<?xml version='1.0' encoding='utf-8'?>
<document id="30125353"><sentence text="Pharmacokinetics-Pharmacodynamics of High-Dose Ivermectin with Dihydroartemisinin-Piperaquine on Mosquitocidal Activity and QT-Prolongation (IVERMAL)."><entity charOffset="63-93" id="DDI-PubMed.30125353.s1.e0" text="Dihydroartemisinin-Piperaquine" /></sentence><sentence text="High-dose ivermectin, co-administered for 3 days with dihydroartemisinin-piperaquine (DP), killed mosquitoes feeding on individuals for at least 28 days posttreatment in a recent trial (IVERMAL), whereas 7 days was predicted pretrial"><entity charOffset="10-20" id="DDI-PubMed.30125353.s2.e0" text="ivermectin" /><entity charOffset="54-72" id="DDI-PubMed.30125353.s2.e1" text="dihydroartemisinin" /><entity charOffset="73-84" id="DDI-PubMed.30125353.s2.e2" text="piperaquine" /><pair ddi="false" e1="DDI-PubMed.30125353.s2.e0" e2="DDI-PubMed.30125353.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30125353.s2.e0" e2="DDI-PubMed.30125353.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30125353.s2.e0" e2="DDI-PubMed.30125353.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30125353.s2.e1" e2="DDI-PubMed.30125353.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30125353.s2.e1" e2="DDI-PubMed.30125353.s2.e2" /></sentence><sentence text=" The current study assessed the relationship between ivermectin blood concentrations and the observed mosquitocidal effects against Anopheles gambiae s"><entity charOffset="53-63" id="DDI-PubMed.30125353.s3.e0" text="ivermectin" /></sentence><sentence text="s" /><sentence text=" Three days of ivermectin 0, 300, or 600 mcg/kg/day plus DP was randomly assigned to 141 adults with uncomplicated malaria in Kenya"><entity charOffset="15-25" id="DDI-PubMed.30125353.s5.e0" text="ivermectin" /></sentence><sentence text=" During 28 days of follow-up, 1,393 venous and 335 paired capillary plasma samples, 850 mosquito-cluster mortality rates, and 524 QTcF-intervals were collected" /><sentence text=" Using pharmacokinetic/pharmacodynamic (PK/PD) modeling, we show a consistent correlation between predicted ivermectin concentrations and observed mosquitocidal-effects throughout the 28-day study duration, without invoking an unidentified mosquitocidal metabolite or drug-drug interaction"><entity charOffset="108-118" id="DDI-PubMed.30125353.s7.e0" text="ivermectin" /></sentence><sentence text=" Ivermectin had no effect on piperaquine's PKs or QTcF-prolongation"><entity charOffset="1-11" id="DDI-PubMed.30125353.s8.e0" text="Ivermectin" /></sentence><sentence text=" The PK/PD model can be used to design new treatment regimens with predicted mosquitocidal effect" /><sentence text=" This methodology could be used to evaluate effectiveness of other endectocides" /><sentence text="" /></document>